VERTEX PHARMACEUTICALS Aktie

>VRTX Aktienkurs

378.95 EUR -1.8% (TradegateBSX)

Ask: 380.75 EUR / 250 Stück

Bid: 379.9 EUR / 400 Stück

Tagesumsatz: 85 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

VRTX Aktie über LYNX handeln

Intraday

1 Jahr

>VRTX Performance

1 Woche: -0,5%

1 Monat: -7,2%

3 Monate: -1,6%

6 Monate: +9,5%

1 Jahr: -14,1%

laufendes Jahr: -3,3%

>VERTEX PHARMACEUTICALS Aktie

Name:

VERTEX PHARMACEUTICALS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US92532F1003 / 882807

Symbol/ Ticker:

VX1 (Frankfurt) / VRTX (NASDAQ)

Kürzel:

FRA:VX1, ETR:VX1, VX1:GR, NASDAQ:VRTX

Index:

S&P500, Nasdaq100

Webseite:

https://www.vrtx.com/

Profil:

Vertex Pharmaceuticals Incorporated is a leading biotechnology company founded in 1989 and headquartered in Boston, Massachusetts. It specializes in the discovery, development, and commercialization of transformative therapies, with a primary focus o..
>Volltext..

Marktkapitalisierung:

98430.1 Mio. EUR

Unternehmenswert:

94536.54 Mio. EUR

Umsatz:

10460.4 Mio. EUR

EBITDA:

4303.76 Mio. EUR

Nettogewinn:

3424.72 Mio. EUR

Gewinn je Aktie:

13.4 EUR

Schulden:

1763.82 Mio. EUR

Liquide Mittel:

4407.64 Mio. EUR

Operativer Cashflow:

3145.94 Mio. EUR

Bargeldquote:

1.71

Umsatzwachstum:

-3.11%

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

2 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 4.642.998 USD.

Suchwörter:

VERTEX PHARMACEUTICALS, VERTEX PHARMA, VRTX

Letzte Datenerhebung:

04.04.26

>VRTX Kennzahlen

Aktien/ Unternehmen:

Aktien: 254.03 Mio. St.

Frei handelbar: 99.67%

Leerverk. Aktien: 1.62%

Rückkaufquote: 1.66%

Mitarbeiter: 6400

Umsatz/Mitarb.: 1.63 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 24.2%

Bewertung:

KGV: 29.41

KGV lG: 22.93

KUV: 9.42

KBV: 6.14

PEG-Ratio: -

EV/EBITDA: 21.97

Rentabilität:

Bruttomarge: 86.32%

Gewinnmarge: 32.74%

Operative Marge: 39.43%

Managementeffizenz:

Gesamtkaprendite: 16.06%

Eigenkaprendite: 22.54%

>VRTX Peer Group

Gesundheit

>VRTX Chart & Kurs - NASDAQ

>VRTX News

03.04.26 - 01:45	Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
	Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $438.75, moving 1.9% from the previous trading session....

01.04.26 - 14:31	Vertex Pharma wins FDA label expansion for cystic fibrosis therapies (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

01.04.26 - 02:01	Insiderhandel: EVP and CMO verkauft Aktien von Vertex Pharmaceuticals im Wert von 1050263 USD (Insiderkauf)
	Bozic, Carmen - Vorstand - Tag der Transaktion: 2026-03-27...

31.03.26 - 00:18	If You Invested $1000 In Vertex Pharmaceuticals Stock 15 Years Ago, You Would Have This Much Today (Benzinga)
	Importance Rank: 1 read more...

26.03.26 - 00:45	Vertex Pharmaceuticals (VRTX) Laps the Stock Market: Here′s Why (Zacks)
	Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $454.97, signifying a +1.42% move from its prior day's close....

25.03.26 - 21:36	Where Will Vertex Pharmaceuticals Be in 1 Year? (Fool)
	The biotech's recent dip might be a buying opportunity....

20.03.26 - 16:42

Vertex Pharmaceuticals Aktie: Drei neue Wachstumstreiber! (Aktiencheck)

New York (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse der Maxim Group: Maxim habe die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN: 882807, Ticker-Symbol: VX1, NASDAQ-Symbol: VRTX) von "hold" auf "buy" hochgestuft und ein Kursziel von 575 USD vergeben. Die Bank sei der Ansicht, dass Povetacicept ein Blockbuster würden und das Potenzial einer Pipeline in einem Produkt haben könnte. [mehr]...

20.03.26 - 14:15	Vertex Stock Falls 4.8% in a Month: Buying Opportunity or Red Flag? (Zacks)
	VRTX stock slips nearly 5% as concerns over new drug uptake and pipeline setbacks weigh, even as its dominant CF franchise continues to drive steady growth....

19.03.26 - 20:00	Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals (Fool)
	Both have plenty to offer investors, but one has a better outlook....

19.03.26 - 00:45	Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
	In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $451.59, denoting a -2.36% move from the preceding trading day....

18.03.26 - 01:01	Insiderhandel: EVP and CMO verkauft Aktien von Vertex Pharmaceuticals im Wert von 1122089 USD (Insiderkauf)
	Bozic, Carmen - Vorstand - Tag der Transaktion: 2026-03-13...

16.03.26 - 02:49	Is Vertex Pharmaceuticals Heading to $600? (Fool)
	A new product approval may be right around the corner....

13.03.26 - 23:01	Insiderhandel: EVP, Chief Commercial Officer verkauft Aktien von Vertex Pharmaceuticals im Wert von 1312340 USD (Insiderkauf)
	Mckechnie, Duncan - Vorstand - Tag der Transaktion: 2026-03-11...

13.03.26 - 15:45	Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
	Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects....

13.03.26 - 00:15	If You Invested $1000 In Vertex Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today (Benzinga)
	Importance Rank: 1 read more...

12.03.26 - 16:54	Vertex Pharmaceuticals Aktie: Phase-3-Daten sorgen für Aufsehen (Aktiencheck)
	Charlotte, NC (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von Truist: Der Truist-Analyst Joon Lee habe das Kursziel für die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN: 882807, Ticker-Symbol: VX1, NASDAQ-Symbol: VRTX) von 490 auf 525 USD angehoben und das "buy"-Rating bestätigt. [mehr]...

12.03.26 - 15:15

AM Best Affirms Credit Ratings of Torreyana Insurance Company, Inc. (Business Wire)

OLDWICK, N.J.--(BUSINESS WIRE)--#insurance--AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of “a” (Excellent) of Torreyana Insurance Company, Inc. (TIC) (Burlington, VT). The outlook of these Credit Ratings (ratings) is stable. The ratings reflect TIC's balance sheet strength, which AM Best assesses as very strong, as well as its strong operating performance, neutral business profile and appropriate enterprise risk management (ERM). The very strong balance sheet strength assessment of TIC is supported by the strongest level of risk-adjusted capitalization, as measured by Best's Capital Adequacy Ratio (BCAR). TIC has a highly liquid investment portfolio that consists predominantly of cash and cash equivalents. In 2025, the company added a loan back to its parent, Vertex Pharmaceuticals Incorporated (Vertex). The growth in TIC's surplus is funded largely with internally generated capital from profitable underwriting and overall operations wh...

12.03.26 - 00:45	Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
	The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $492.38, representing a -1.36% change from its previous close....

11.03.26 - 15:45	Company News for Mar 11, 2026 (Zacks)
	Companies in The News Are: KSS,UNFI,CASY,VRTX...

11.03.26 - 15:45	Vertex (VRTX) Moves 8.3% Higher: Will This Strength Last? (Zacks)
	Vertex (VRTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram